Soluble CD40L levels are regulated by the -3459 A>G polymorphism and predict myocardial infarction and the efficacy of antithrombotic treatment in non-ST elevation acute coronary syndrome

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 26, Issue 7, 2006, Pages 1667-1673

  Mälarstig, Anders ^a   Lindahl, Bertil ^a   Wallentin, Lars ^a   Siegbahn, Agneta ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

ACS; CD40L; Myocardial infarction; Outcome; SNP; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BIOLOGICAL MARKER; CD40 LIGAND; DALTEPARIN; PLACEBO; TROPONIN T; FIBRINOLYTIC AGENT;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CONCENTRATION (PARAMETERS); CONSERVATIVE TREATMENT; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG EFFICACY; FEMALE; GENE CONTROL; HEART INFARCTION; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; ST SEGMENT ELEVATION; THROMBOSIS; ACUTE DISEASE; BLOOD; CHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; ELECTROCARDIOGRAPHY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENETICS; MIDDLE AGED; MULTICENTER STUDY; NUCLEOTIDE SEQUENCE; OSMOLARITY; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SOLUBILITY; SURVIVAL; SYNDROME; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; BIOLOGICAL MARKERS; CD40 LIGAND; CORONARY DISEASE; DALTEPARIN; ELECTROCARDIOGRAPHY; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; OSMOLAR CONCENTRATION; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; SOLUBILITY; SURVIVAL ANALYSIS; SYNDROME; TREATMENT OUTCOME; TROPONIN T; VARIATION (GENETICS);

EID: 33745946908     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000222908.78873.36     Document Type: Article

References (32)

1. Viles-Gonzalez JF, Fuster V, Badimon JJ. Atherothrombosis: a widespread disease with unpredictable and life-threatening consequences. Eur Heart J. 2004;25:1197-1207.
2. Phipps RP. Atherosclerosis: the emerging role of inflammation and the CD40-CD40 ligand system. Proc Natl Acad Sci U S A. 2000;97:6930-6932.
3. Lindmark E, Diderholm E, Wallentin L, Siegbahn A. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA. 2001;286:2107-2113.
4. Lindahl B, Venge P, Wallentin L. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group. J Am Coll Cardiol. 1997;29:43-48.
5. Hamm CW, Heeschen C, Goldmann B et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. N Engl J Med. 1999;340:1623-1629.
6. Newby LK, Goldmann BU, Ohman EM Troponin: an important prognostic marker and risk-stratification tool in non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol. 2003;41:31S-36S.
7. James SK, Lindahl B, Siegbahn A et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV Substudy. Circulation. 2003;108:275-281.
8. Henn V, Slupsky JR, Grafe M et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998;391:591-594.
9. Szabolcs MJ, Cannon PJ, Thienel U et al. Analysis of CD154 and CD40 expression in native coronary atherosclerosis and transplant associated coronary artery disease. Virchows Arch. 2000;437:149-159.
10. Buchner K, Henn V, Grafe M, de Boer OJ, Becker AE, Kroczek RA. CD40 ligand is selectively expressed on CD4+ T cells and platelets: implications for CD40-CD40L signalling in atherosclerosis. J Pathol. 2003;201:288-295.
11. Otterdal K, Pedersen TM, Solum NO. Release of soluble CD40 ligand after platelet activation: studies on the solubilization phase. Thromb Res. 2004;114:167-177.
12. Mach F, Schonbeck U, Sukhova GK, Atkinson E, Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature. 1998; 394:200-203.
13. Lindmark E, Tenno T, Siegbahn A. Role of platelet P-selectin and CD40 ligand in the induction of monocytic tissue factor expression. Arterioscler Thromb Vasc Biol. 2000;20:2322-2328.
14. Andre P, Prasad KSS, Denis CV et al. CD40L stabilizes arterial thrombi by a beta(3) integrin-dependent mechanism. Nature Medicine. 2002;8:247-252.
15. Varo N, de Lemos JA, Libby P et al. Soluble CD40L: risk prediction after acute coronary syndromes. Circulation. 2003;108:1049-1052.
16. Heeschen C, Dimmeler S, Hamm CW et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med. 2003;348:1104-1111.
17. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease. Investigators. Lancet. 1999;354:701-707.
18. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet. 1999;354:708-715.
19. Lagerqvist B, Husted S, Kontny F et al. A long-term perspective on the protective effects of an early invasive strategy in unstable coronary artery disease: two-year follow-up of the FRISC-II invasive study. J Am Coll Cardiol. 2002;40:1902-1914.
20. Jernberg T, Lindahl B, Siegbahn A et al. N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease. J Am Coll Cardiol. 2003;42:1909-1916.
21. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
22. Oldgren J, Fellenius C, Boman K et al. Influence of prolonged dalteparin treatment on coagulation, fibrinolysis and inflammation in unstable coronary artery disease. J Intern Med. 2005;258:420-427.
23. Viallard JF, Solanilla A, Gauthier B et al. Increased soluble and platelet-associated CD40 ligand in essential thrombocythemia and reactive thrombocytosis. Blood. 2002;99:2612-2614.
24. Farndale RW. Collagen-induced platelet activation. Blood Cells Mol Dis. 2006;online February 4.
25. Schonbeck U, Mach F, Sukhova GK et al. CD40 ligation induces tissue factor expression in human vascular smooth muscle cells. Am J Pathol. 2000;156:7-14.
26. Harding SA, Sommerfield AJ, Sarma J et al. Increased CD40 ligand and platelet-monocyte aggregates in patients with type 1 diabetes mellitus. Atherosclerosis. 2004;176:321-325.
27. Jinchuan Y, Zonggui W, Jinming C, Li L, Xiantao K. Upregulation of CD40-CD40 ligand system in patients with diabetes mellitus. Clin Chim Acta. 2004;339:85-90.
28. Sanguigni V, Pignatelli P, Lenti L et al. Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation. 2005;111:412-419.
29. Blann AD, Tan KT, Tayebjee MH, Davagnanam I, Moss M, Lip GY. Soluble CD40L in peripheral artery disease. Relationship with disease severity, platelet markers and the effects of angioplasty. Thromb Haemost. 2005;93:578-583.
30. Schonbeck U, Libby P. CD40 signaling and plaque instability. Circ Res. 2001;89:1092-1103.
31. Aukrust P, Muller F, Ueland T et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina - Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation. 1999;100:614-620.
32. de Lemos JA, Zirlik A, Schonbeck U et al. Associations between soluble CD40 ligand, athrosclerosis risk factors, and subclinical atherosclerosis. Results from the Dallas Heart Study. Arterioscler Thromb Vasc Biol. 2005;25:2192-2196.